The necessity of bridging of anticoagulation for patients with AF using LMWH has been a controversial area. The BRIDGE trial, a randomised, controlled trial which involved almost 2000 patients was published in the New England Journal (22/06/15). The authors concluded that “In patients with atrial fibrillation who had warfarin treatment interrupted for an elective operation or other elective invasive procedure, forgoing bridging anticoagulation was noninferior to perioperative bridging with low-molecular-weight heparin for the prevention of arterial thromboembolism and decreased the risk of major bleeding.”
World Thrombosis Day may seem some way off but it is never too early to make a plan. There are lots of great ideas for promoting VTE awareness on the new website http://www.worldthrombosisday.org/. CLOT are pleased to support this important global event.
Members of the CLOT Committee and two CLOT members awarded a travel scholarship visited the ISTH conference in Toronto between 21st and 25th June. This year's conference included a busy two-day nurses and allied health professionals sessions where a vast number of topics from anticoagulation to haemophilia were covered by delegates from all over the world.
CLOT were pleased to award Sarah Bond, Anticoagulation pharmacist/anticoagulant service lead from Swindon and VTE nurse manager Kay Sumner from Lincoln with travel scholarships to attend the meeting. Both showed that they had been forward-thinking and innovative in their practice and would benefit from the opportunity to learn from and network with with international colleagues. Both will share their experience at this year's CLOT meeting.
Jo Boyd (pictured below), a CLOT member, presented a very interesting talk on the development of a community-based nurse-led Ultrasound scanning service for DVT which showed how sharing practice, education and crossing boundaries can vastly improve services.
Sue Rhodes, also a longstanding CLOT member, presented a talk on Shared decision making in Anticoagulant Management and also presented a poster, along with Sarah Bond, on their audit of the use of the DOAC drugs in their clinics in Swindon.
Huw Rowswell, the CLOT Secretary, presented a poster about his work on the comparison of risk factors and outcomes in community vs hospital acquired thrombosis.
Well done to all of them for having shared their work with a worldwide audience; it is very inspiring to see how UK practice often seems to lead the way.
Our latest newsletter is ready to read in the Members' library. An email copy will be on its way to you soon.
The current issue of The Lancet (09/06/15) contains 2 articles concerned with the results of the ENGAGE-AF trial of Edoxaban, a Factor Xa inhibitor, for use in patients in AF.